Full Year 2022 Terumo Corp Earnings Call Transcript
I am the CFO, Muto. I will now explain the results for the fiscal year ending March 2022. First, here is the highlights of this financial statement.
In sales revenue, Japan saw factors, including a return to normal of infection prevention product demand, resulting in a slight increase. However, regions outside Japan and FX rates drove the Q4 and year-to-date sales results to our highest ever. In adjusted operating profit, although negative impacts I anticipated at the beginning of the year, combined with inflation and reduced factory utilization as downward factors, the contributions of strong overseas sales and FX rates resulted in an annual result of 16% year-on-year growth.
Our FY '22 guidance anticipates double-digit growth in both sales revenue and profit. In sales revenue, the number of procedures and other demand are expected to emerge from COVID impact, driving growth in each company. FX rates are also expected to have a positive impact. Although inflation impact will occur throughout the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |